Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%

by Zacks Equity Research

Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down

    by Zacks Equity Research

    BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.

      Company News For Aug 9, 2018

      by Zacks Equity Research

      Companies In The News are: KORS,XEC,DDD,ENDP

        Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance

        by Zacks Equity Research

        Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.

          Implied Volatility Surging for Endo International (ENDP) Stock Options

          by Zacks Equity Research

          Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

            Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates

            by Zacks Equity Research

            Endo (ENDP) delivered earnings and revenue surprises of 38.18% and 4.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

              Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?

              by Zacks Equity Research

              During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.

                What's in Store for Catalyst (CPRX) This Earnings Season?

                by Zacks Equity Research

                Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.

                  What's in Store for Intrexon (XON) This Earnings Season?

                  by Zacks Equity Research

                  Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

                    What's in Store for Epizyme (EPZM) This Earnings Season?

                    by Zacks Equity Research

                    Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.

                      Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?

                      by Zacks Equity Research

                      We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.

                        Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                        by Zacks Equity Research

                        In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.

                          What's in Store for Immune Design (IMDZ) in Q2 Earnings?

                          by Zacks Equity Research

                          We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.

                            Is a Beat in Store for Endocyte (ECYT) This Earnings Season?

                            by Zacks Equity Research

                            The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.

                              Is Endo International a Great Stock for Value Investors?

                              by Zacks Equity Research

                              Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.

                                Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

                                by Zacks Equity Research

                                Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

                                  Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

                                  by Zacks Equity Research

                                  Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.

                                    BioMarin Begins Pediatric Study on Achondroplasia Candidate

                                    by Zacks Equity Research

                                    BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.

                                      Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?

                                      by Zacks Equity Research

                                      Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

                                        by Zacks Equity Research

                                        BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

                                          Ekta Bagri headshot

                                          Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

                                          by Ekta Bagri

                                          Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

                                            Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

                                            by Zacks Equity Research

                                            Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

                                              Factors Likely to Impact Zillow (ZG) This Earnings Season

                                              by Zacks Equity Research

                                              Zillow (ZG) to benefit from increasing traffic at its mobile apps and websites, strong rental demand and expanding Multiple Listing Services partnerships.

                                                Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?

                                                by Zacks Equity Research

                                                Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.

                                                  What Falling Estimates & Price Mean for Endo International (ENDP)

                                                  by Zacks Equity Research

                                                  Endo International (ENDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.